Stelara vs Ibrance
Side-by-side drug price comparison from Medicare Part D data
Verdict
Stelara costs 28% less per claim than Ibrance ($7763.00 vs $10816.00). Stelara has a generic alternative available. Total Medicare spending: Stelara at $5.6B vs Ibrance at $4.5B.
| Metric | Stelara | Ibrance |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $7,763* | $10,816 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.6B | $4.5B |
| Total Claims | 720,000 | 418,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 6.3% | -5.6%* |
| Generic Available | Yes | Yes |
| Condition | Autoimmune Diseases | Cancer |
| Total Beneficiaries | 114,000 | 36,000 |
Stelara costs 28% less per claim than Ibrance ($7763.00 vs $10816.00). Stelara has a generic alternative available. Total Medicare spending: Stelara at $5.6B vs Ibrance at $4.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Stelara and Ibrance. What follows is the interpretation — which specific axes carry the most weight for Stelara versus Ibrance, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.